A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Blackstone follows Abingworth, but why?
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
